Overall survival analysis from a randomised phase III trial of axitinib vs sorafenib as first-line therapy in patients with metastatic renal cell ca...

Date 27 September 2015
Event European Cancer Congress 2015
Session Genitourinary Malignancies - Prostate and Nonprostate Cancer
Topics Renal Cell Cancer
Presenter Hutson, T.